Blood first assay screening trial (BFAST) in patients (pts) with 1L NSCLC: ALK plus cohort updated biomarker analyses

被引：1
|
作者：
Gadgeel, S. M. [1 ]
Yan, M. [2 ]
Paul, S. M. [3 ]
Mathisen, M. [4 ]
Mocci, S. [3 ]
Assaf, Z. J. [3 ]
Patel, R. [3 ]
Sokol, E. S. [5 ]
Mok, T. [6 ]
Peters, S. [7 ]
Paz-Ares, L. [8 ]
Dziadziuszko, R. [9 ]
机构：
[1] Henry Ford Hosp, Henry Ford Canc Inst, Dept Internal Med, Detroit, MI 48202 USA
[2] F Hoffmann La Roche & Cie AG, Biometr, Mississauga, ON, Canada
[3] Genentech Inc, Oncol Biomarker Dev, San Francisco, CA 94080 USA
[4] Genentech Inc, Prod Dev Oncol Clin Sci, San Francisco, CA 94080 USA
[5] Fdn Med Inc, Canc Genom, Cambridge, MA USA
[6] Chinese Univ Hong Kong, Dept Clin Oncol, State Key Lab South China, Hong Kong, Peoples R China
[7] Ctr Hosp Univ Vaudois CHUV, Multidisciplinary Oncol Ctr, Lausanne, Switzerland
[8] Univ Hosp 12 Octubre, Med Oncol, Madrid, Spain
[9] Med Univ Gdansk, Oncol & Radiotherapy, Gdansk, Poland
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1615
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1301P
引用
收藏
页码：S841 / S841
页数：1
相关论文
共 50 条
  • [21] ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK plus non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo)
    Solomon, B. J.
    Wu, Y-L.
    Dziadziuszko, R.
    Barlesi, F.
    Nishio, M.
    Ahn, J. S.
    Horinouchi, H.
    Hochmair, M. J.
    de Marinis, F.
    Migliorino, M. R.
    Kurochkin, A.
    Harputluoglu, H.
    Planchard, D.
    Korphaisarn, K.
    Han, J-Y.
    Lohmann, T.
    Gavaldon, A. Cardona
    Archer, V. R.
    Nowicka, M.
    Noe, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S775 - S775
  • [22] RATIONALE-307: Updated Biomarker Analysis of Phase 3 Study of Tislelizumab Plus Chemo vs Chemo Alone For 1L Advanced Sq-NSCLC
    Wang, J.
    Lu, S.
    Wang, Z.
    Hu, C.
    Sun, Y.
    Yang, K.
    Chen, M.
    Zhao, J.
    Liang, L.
    Huo, Y.
    Zhang, Y.
    Huang, R.
    Wu, X.
    Ma, X.
    Leaw, S. J.
    Bai, F.
    Shen, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S950 - S951
  • [23] Blood-based genomic profiling of advanced non-small cell lung cancer (aNSCLC) patients (pts) from blood first assay screening trial (BFAST) and comparison with real-world data (RWD)
    Dziadziuszko, R.
    Zhang, Q.
    Li, X.
    Paul, S. M.
    Sugidono, M.
    Mocci, S.
    Kinkolykh, A.
    Shames, D. S.
    Archer, V.
    Mathisen, M. S.
    Jin, D. X.
    Gadgeel, S. M.
    Peters, S.
    Mok, T.
    ANNALS OF ONCOLOGY, 2020, 31 : S845 - S846
  • [24] Five-year outcomes with first-line (1L) nivolumab plus ipilimumab plus chemotherapy (N plus I plus C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA.
    Reck, Martin
    Ciuleanu, Tudor-Eliade
    Schenker, Michael
    Bordenave, Stephanie
    Cobo, Manuel
    Juan-Vidal, Oscar
    Reinmuth, Niels
    Richardet, Eduardo
    Felip, Enriqueta
    Menezes, Juliana
    Cheng, Ying
    Mizutani, Hideaki
    Carbone, David Paul
    Lu, Shun
    John, Tom
    Aoyama, Takekazu
    Mahmood, Javed
    Hu, Nan
    Eccles, Laura
    Paz-Ares, Luis G.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] A real-world study to explore therapeutic changing mode of locally therapy during 1L lorlatinib treatment in unresectable ALK plus NSCLC patients
    Zhao, J.
    Yang, X.
    Zhai, X.
    ANNALS OF ONCOLOGY, 2024, 35
  • [26] Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK plus ) non-small cell lung cancer (NSCLC) in a phase 1/2 trial
    Rosell, R.
    Gettinger, S. N.
    Bazhenova, L. A.
    Langer, C. J.
    Salgia, R.
    Shaw, A. T.
    Narasimhan, N. I.
    Dorer, D. J.
    Kerstein, D.
    Camidge, D. R.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S114 - S114
  • [27] Experience from the ASCEND-1 trial: Ceritinib in patients (Pts) with ALK-rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC) and brain metastases
    Thomas, M.
    Schuler, M.
    Potzner, M.
    Szczudlo, T.
    Sutradhar, S.
    Yovine, A.
    Wolf, J.
    Oncology Research and Treatment, 2015, 38 : 270 - 270
  • [28] Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK1 NSCLC: Updated results from the phase III ALTA-1L trial
    Camidge, R.
    Kim, H. R.
    Ahn, M-J.
    Yang, J. C-H.
    Han, J-Y.
    Hochmair, M. J.
    Lee, K. H.
    Delmonte, A.
    Garcia Campelo, M. R.
    Kim, D-W.
    Griesinger, F.
    Felip, E.
    Califano, R.
    Spira, A.
    Gettinger, S.
    Tiseo, M.
    Ni, Q.
    Zhang, P.
    Popat, S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [29] Updated analysis from the KEYNOTE-042 China study: 1L pembrolizumab (pembro) vs chemotherapy (chemo) in Chinese patients (pts) with advanced NSCLC with PD-L1 TPS ≥1%
    Wu, Y-L.
    Zhang, L.
    Fan, Y.
    Zhou, J.
    Zhang, L.
    Zhou, Q.
    Li, W.
    Hu, C.
    Chen, G.
    Zhang, X.
    Zhou, C.
    Souza, F.
    Lin, J.
    Wang, J.
    Li, B.
    Mok, T.
    ANNALS OF ONCOLOGY, 2020, 31 : S1394 - S1394
  • [30] Updated Results from the Phase 3 ALTA-1L Trial of Brigatinib (BRG) vs. Crizotinib (CRZ) in ALK Inhibitor-Naive Advanced ALK plus NSCLC
    Griesinger, Frank
    Camidge, D. Ross
    Kim, Hye Ryun
    Ahn, Myung-Ju
    Yang, James Chih-Hsin
    Han, Ji Youn
    Hochmair, Maximilian
    Lee, Hyeong
    Delmonte, Angelo
    Garcia Compelo, Maria Rosario
    Kim, Dong-Wan
    Felip, Enriqueta
    Califano, Raffaele
    Spire, Alexander
    Gettinger, Scott N.
    Tiseo, Marcello
    Lin, Huamao M.
    Ni, Quanhong
    Zhang, Pingkuan
    Popat, Sanjay
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 232 - 232
12345